Objective To evaluate the efficacy of Cobalt 60 radiotherapy in patients with stage I and II non small cell lung cancer. Methods From March 1977 to December 1992, 63 patients with stage I and II non small cell lung cancer were treated. According to the 1997 UICC staging system, 7 patients had stage IA disease, 10 stage IB, 5 stage IIA, and 41 stage IIB. Forty nine patients were confirmed by histopathology, and 14 cases by cytopathology. Fifty eight patients had squamous cell carcinoma, 3 adenocarcinoma, and 2 mixed squamous cell and adenocarcinama. All patients were treated by Cobalt 60. Patients would receive 40 Gy plus a boost of 15～30 Gy. The total dose was D T55～70 Gy in 6～12 weeks. All patients were followed for more than five years. Results The overall 5 year survival for all patients was 17.5%. Fifty eight (92%) patients have died and 11 survived. For the 58 succumbed patients, 52 (90%) died of tumor, and 26 (45%) of them from local failure. Four patients (7%) died of other causes. Conclusion Radiotherapy is an effective treatment option for non small cell lung cancer.

BACKGROUND: LY01005 (Goserelin acetate sustained-release microsphere injection) is a modified gonadotropin-releasing hormone (GnRH) agonist injected monthly. This phase III trial study aimed to evaluated the efficacy and safety of LY01005 in Chinese patients with prostate cancer. METHODS: We conducted a randomized controlled, open-label, non-inferiority trial across 49 sites in China. This study included 290 patients with prostate cancer who received either LY01005 or goserelin implants every 28 days for three injections. The primary efficacy endpoints were the percentage of patients with testosterone suppression ≤50 ng/dL at day 29 and the cumulative probability of testosterone ≤50 ng/dL from day 29 to 85. Non-inferiority was prespecified at a margin of -10%. Secondary endpoints included significant castration (≤20 ng/dL), testosterone surge within 72 h following repeated dosing, and changes in luteinizing hormone, follicle-stimulating hormone, and prostate specific antigen levels. RESULTS: On day 29, in the LY01005 and goserelin implant groups, testosterone concentrations fell below medical-castration levels in 99.3% (142/143) and 100% (140/140) of patients, respectively, with a difference of -0.7% (95% confidence interval [CI], -3.9% to 2.0%) between the two groups. The cumulative probabilities of maintaining castration from days 29 to 85 were 99.3% and 97.8%, respectively, with a between-group difference of 1.5% (95% CI, -1.3% to 4.4%). Both results met the criterion for non-inferiority. Secondary endpoints were similar between groups. Both treatments were well-tolerated. LY01005 was associated with fewer injection-site reactions than the goserelin implant (0% vs . 1.4% [2/145]). CONCLUSION: LY01005 is as effective as goserelin implants in reducing testosterone to castration levels, with a similar safety profile. TRIAL REGISTRATION ClinicalTrials.gov, NCT04563936.
Humans ; Male ; Antineoplastic Agents, Hormonal/therapeutic use* ; East Asian People ; Gonadotropin-Releasing Hormone/agonists* ; Goserelin/therapeutic use* ; Prostate-Specific Antigen ; Prostatic Neoplasms/drug therapy* ; Testosterone